Rebiotics Rx

Company Overview

Snapshot

Founded in February 2018, Rebiotics Rx operated with 1-10 employees. The company secured funding across one round from one investor, Integra Holdings. In May 2021, Rebiotics Rx ceased operations.

Business overview

Rebiotics Rx specializes in the Health Tech & Life Sciences sector, focusing on repurposing existing FDA-approved antibiotics to combat antibiotic-resistant bacteria. Its core technology involves a PEGylated Nanoliposomal-mupirocin formulation, designed to enhance the systemic activity of mupirocin, an antibiotic effective against critical public health threats like MRSA. By reformulating mupirocin, Rebiotics Rx aims to enable its parenteral use, thereby addressing the limitations of its short half-life and expanding its application beyond topical uses. The company operates within the Drugs Discovery & Development segment of the Pharma & Medical Biotechnology market.

Company Intelligence Q&A

What is Rebiotics Rx's primary focus?

Rebiotics Rx focuses on repurposing existing FDA-approved antibiotics to combat antibiotic-resistant bacteria, specifically developing a PEGylated Nanoliposomal-mupirocin formulation.

When was Rebiotics Rx founded?

Rebiotics Rx was founded in February 2018.

What is the status of Rebiotics Rx?

Rebiotics Rx is non-active and ceased to operate in May 2021.

What was a key technological development for Rebiotics Rx?

In February 2018, Rebiotics Rx developed a novel computational method for the identification of drug candidates suitable for liposomal reformulation, focusing on nanotechnology and drug delivery within Pharmaceuticals & Diagnostics.

Which accelerator program did Rebiotics Rx graduate from?

Rebiotics Rx graduated from the SigmaLabs Accelerator in November 2020 as part of its 13th batch.